Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Cash from Operations (2019 - 2025)

Revolution Medicines (RVMD) has 7 years of Cash from Operations data on record, last reported at 274238000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations fell 98.31% year-over-year to 274238000.0; the TTM value through Dec 2025 reached 897741000.0, down 61.05%, while the annual FY2025 figure was 897741000.0, 61.05% down from the prior year.
  • Cash from Operations reached 274238000.0 in Q4 2025 per RVMD's latest filing, down from 207311000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 34081000.0 in Q2 2021 and bottomed at 274238000.0 in Q4 2025.
  • Average Cash from Operations over 5 years is 108866500.0, with a median of 83809000.0 recorded in 2023.
  • Peak YoY movement for Cash from Operations: fell 13.11% in 2023, then plummeted 157.34% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 39265000.0 in 2021, then tumbled by 57.36% to 61788000.0 in 2022, then tumbled by 95.12% to 120563000.0 in 2023, then decreased by 14.7% to 138290000.0 in 2024, then tumbled by 98.31% to 274238000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 274238000.0 in Q4 2025, 207311000.0 in Q3 2025, and 221757000.0 in Q2 2025.